MedKoo product information:

 Nedaplatin

nedaplatin is a second-generation cisplatin analogue with antineoplastic activity. Containing a novel ring structure in which glycolate is bound to the platinum by a bidentate ligand, nedaplatin forms reactive platinum complexes that bind to nucelophillic groups in DNA, resulting in intrastrand and interstrand DNA cross-links, apoptosis and cell death. This agent appears to be less nephrotoxic and neurotoxic compared to both cisplatin and carboplatin. Check for active clinical trials or closed clinical trials using this agent. (NCI Thesaurus)  

 1: Wheate NJ, Walker S, Craig GE, Oun R. The status of platinum anticancer drugs in the clinic and in clinical trials. Dalton Trans. 2010 Jun 30. [Epub ahead of print] PubMed PMID: 20593091.

2: Miura T, Hosojima Y, Nakamura J, Yamada S, Nakazawa Y, Ozeki Y, Miura T, Yanagi M, Yamazaki H, Takahashi T. [An elderly hemodialytic case of recurrent esophageal cancer given combination chemotherapy with docetaxel and nedaplatin who showed temporal relief of swallowing disturbance]. Gan To Kagaku Ryoho. 2010 May;37(5):883-5. Japanese. PubMed PMID: 20495320.

3: Zhang J, Wang L, Xing Z, Liu D, Sun J, Li X, Zhang Y. Status of bi- and multi-nuclear platinum anticancer drug development. Anticancer Agents Med Chem. 2010 May 1;10(4):272-82. PubMed PMID: 20184553.

4: Iijima S, Makari Y, Kato T, Ooshima S, Hoshi M, Doi T, Miyake Y, Sakamoto T, Kato A, Miyo M, Kurokawa E, Kikkawa N. [A case of a 14-month survival patient on advanced esophageal cancer with uncontrolled brain metastasis completely responding to nedaplatin, adriamycin, plus 5-FU (NAF) therapy]. Gan To Kagaku Ryoho. 2009 Nov;36(12):2052-4. Japanese. PubMed PMID: 20037320.

5: Zhang J, Liu D, Li Y, Sun J, Wang L, Zang A. Status of non-classical mononuclear platinum anticancer drug development. Mini Rev Med Chem. 2009 Oct;9(11):1357-66. Review. PubMed PMID: 19929810.

6: Alberto ME, Lucas MF, Pavelka M, Russo N. The second-generation anticancer drug Nedaplatin: a theoretical investigation on the hydrolysis mechanism. J Phys Chem B. 2009 Oct 29;113(43):14473-9. PubMed PMID: 19778071.

7: Nishime C, Ohnishi Y, Suemizu H, Tamaoki N, Kusumi T, Sato F, Yamazaki H, Nakamura M, Ueyama Y, Kijima H. In vivo chemotherapeutic profile of human gallbladder small cell carcinoma. Biomed Res. 2008 Oct;29(5):251-6. PubMed PMID: 18997440.

8: Tanaka T, Yukawa K, Umesaki N. Radiation reduces carboplatin sensitivity and enhances nedaplatin sensitivity in cervical squamous cell carcinoma in vitro. Eur J Gynaecol Oncol. 2007;28(5):352-5. PubMed PMID: 17966212.

9: Loh GW, Ting LS, Ensom MH. A systematic review of limited sampling strategies for platinum agents used in cancer chemotherapy. Clin Pharmacokinet. 2007;46(6):471-94. Review. PubMed PMID: 17518507.

10: Xu RH, Shi YX, Guan ZZ, Jiang WQ, Huang H, Ma ZY, Wang JH, Hu XH, Xie WM, Li XG, Liu YL, Pan LX, Dai AD, Zhuang W, Zhang C. [Phase II clinical trial of home-produced Nedaplatin in treating advanced esophageal carcinoma]. Ai Zheng. 2006 Dec;25(12):1565-8. Chinese. PubMed PMID: 17166388.

11: Yonezawa A, Masuda S, Yokoo S, Katsura T, Inui K. Cisplatin and oxaliplatin, but not carboplatin and nedaplatin, are substrates for human organic cation transporters (SLC22A1-3 and multidrug and toxin extrusion family). J Pharmacol Exp Ther. 2006 Nov;319(2):879-86. Epub 2006 Aug 16. PubMed PMID: 16914559.

12: Nomoto T, Mizutani Y, Mikami K, Nakamura T, Nakanishi H, Kawauchi A, Miki T. [Salvage chemotherapy with paclitaxel, ifosphamide and nedaplatin for relapsed or refractory germ cell cancer]. Nippon Hinyokika Gakkai Zasshi. 2006 May;97(4):630-5. Japanese. PubMed PMID: 16768143.

13: Tanaka T, Bai T, Yukawa K, Umesaki N. Optimal combination chemotherapy and chemoradiotherapy with etoposide for advanced cervical squamous cancer cells in vitro. Oncol Rep. 2006 Apr;15(4):939-47. PubMed PMID: 16525683.

14: Galanski M, Jakupec MA, Keppler BK. Update of the preclinical situation of anticancer platinum complexes: novel design strategies and innovative analytical approaches. Curr Med Chem. 2005;12(18):2075-94. Review. PubMed PMID: 16101495.

15: Ishibashi T, Yano Y, Oguma T. Determination of optimal dosage for nedaplatin based on pharmacokinetic and toxicodynamic analysis. Anticancer Res. 2005 Mar-Apr;25(2B):1273-81. PubMed PMID: 15865078.

16: Nakamura Y, Momokawa K, Sasaki T, Sakayauchi T, Watanabe T, Mikami T, Matsumoto T. [Effect of steroid on antiemetic for side effect of anticancer chemotherapy]. Gan To Kagaku Ryoho. 2005 Mar;32(3):401-4. Japanese. PubMed PMID: 15791827.

17: Hirao M, Fujitani K, Tsujinaka T. Phase I study of the combination of nedaplatin, adriamycin and 5-fluorouracil for treatment of advanced esophageal cancer. Dis Esophagus. 2004;17(3):247-50. PubMed PMID: 15361099.

18: Ishibashi T, Yano Y, Oguma T. Population pharmacokinetics of platinum after nedaplatin administration and model validation in adult patients. Br J Clin Pharmacol. 2003 Aug;56(2):205-13. PubMed PMID: 12895194; PubMed Central PMCID: PMC1884278.

19: Kanzawa F, Akiyama Y, Saijo N, Nishio K. In vitro effects of combinations of cis-amminedichloro (2-methylpyridine) platinum (II) (ZD0473) with other novel anticancer drugs on the growth of SBC-3, a human small cell lung cancer cell line. Lung Cancer. 2003 Jun;40(3):325-32. PubMed PMID: 12781432.

20: Miki T, Mizutani Y, Nonomura N, Nomoto T, Nakao M, Saiki S, Kotake T, Okuyama A. Irinotecan plus cisplatin has substantial antitumor effect as salvage chemotherapy against germ cell tumors. Cancer. 2002 Nov 1;95(9):1879-85. PubMed PMID: 12404281.

21: Ishibashi T, Yano Y, Oguma T. A formula for predicting optimal dosage of nedaplatin based on renal function in adult cancer patients. Cancer Chemother Pharmacol. 2002 Sep;50(3):230-6. Epub 2002 Jul 3. PubMed PMID: 12203105.

22: Yamashita Y, Goto M, Katsuki T. [Chemotherapy by superselective intraarterial infusion of nedaplatin combined with radiotherapy for oral cancer]. Gan To Kagaku Ryoho. 2002 Jun;29(6):905-9. Japanese. PubMed PMID: 12090042.

23: Nemoto H, Takeuchi S, Yoshizawa Y, Uemichi O, Sasaya S, Yamaguchi M, Makuuchi M, Midorikawa T, Sanada Y, Kumada K, Takizawa K. [Tissue platinum distribution and the effect following intra-arterial injection of cisplatin to metastatic liver cancer--a case report]. Gan To Kagaku Ryoho. 2001 Aug;28(8):1149-53. Japanese. PubMed PMID: 11525035.

24: Kawanishi K, Miyagi Y, Yamamoto J, Miyagi Y, Nakamura K, Kodama J, Hongo A, Yoshinouchi M, Kudo T. Cytocidal effect and DNA damage of nedaplatin in vitro by simulating pharmacokinetic parameters. Cancer Chemother Pharmacol. 2001 Apr;47(4):303-8. PubMed PMID: 11345646.

25: Miyagi Y, Kawanishi K, Miyagi Y, Yamada S, Yamamoto J, Kodama J, Hongo A, Yoshinouchi M, Kudo T. Cytocidal effect and DNA damage of nedaplatin: a mathematical model and analysis of experimental data. Cancer Chemother Pharmacol. 2001 Mar;47(3):229-35. PubMed PMID: 11320666.

26: Kanzawa F, Koizumi F, Koh Y, Nakamura T, Tatsumi Y, Fukumoto H, Saijo N, Yoshioka T, Nishio K. In vitro synergistic interactions between the cisplatin analogue nedaplatin and the DNA topoisomerase I inhibitor irinotecan and the mechanism of this interaction. Clin Cancer Res. 2001 Jan;7(1):202-9. PubMed PMID: 11205910.

27: Kitami A, Suzuki T, Kamio Y, Suzuki S, Hori G, Ueshima Y, Suzuki H. [Thymic carcinoma successfully treated by a combination of intra-arterial infusion chemotherapy and surgery]. Nihon Kokyuki Gakkai Zasshi. 2000 Feb;38(2):122-5. Japanese. PubMed PMID: 10774171.

28: Miki T, Nomoto T, Nakagawa S, Nakao M, Nonomura N, Takada T, Saiki S, Kotake T. [The salvage chemotherapy for refractory testicular cancer with novel anticancer agents]. Hinyokika Kiyo. 1999 Nov;45(11):811-4. Japanese. PubMed PMID: 10637749.

29: Fujii M, Tokumaru Y, Imanishi Y, Kanke M, Kanzaki J, Ohno Y. [Combination chemotherapy with nedaplatin and 5-FU for head and neck cancer]. Gan To Kagaku Ryoho. 1998 Jan;25(1):53-8. Japanese. PubMed PMID: 9464329.

30: Miki T, Sawada M, Nonomura N, Kojima Y, Okuyama A, Maeda O, Saiki S, Kotake T. Antitumor effect of CPT-11, a camptothecin derivative, on human testicular tumor xenografts in nude mice. Eur Urol. 1997;31(1):92-6. PubMed PMID: 9032542.

31: Hong WS, Min YI, Kim HT, Cho YB, Kim KH, Kim DK. Antitumor activity of five new platinum complexes having a glycolate leaving ligand. J Korean Med Sci. 1995 Aug;10(4):269-74. PubMed PMID: 8593207.

32: Heike Y, Takahashi M, Ohira T, Arioka H, Funayama Y, Nishio K, Ogasawara H, Saijo N. In vivo screening models of cisplatin-resistant human lung cancer cell lines using SCID mice. Cancer Chemother Pharmacol. 1995;35(3):200-4. PubMed PMID: 7805177.

33: Ariyoshi Y, Sugiura T. [New promising anticancer drugs for lung cancer]. Gan To Kagaku Ryoho. 1994 Nov;21(15):2578-84. Review. Japanese. PubMed PMID: 7979416.

34: Ogawa M, Ariyoshi Y. New anticancer drugs under clinical trials in Japan. Hematol Oncol Clin North Am. 1994 Apr;8(2):277-87. Review. PubMed PMID: 8040141.

35: Kikkawa F, Kojima M, Oguchi H, Maeda O, Ishikawa H, Tamakoshi K, Mizuno K, Kawai M, Suganuma N, Tomoda Y. Potentiating effect of amphotericin B on five platinum anticancer drugs in human cis-diamminedichloroplatinum (II) sensitive and resistant ovarian carcinoma cells. Anticancer Res. 1993 Jul-Aug;13(4):891-6. PubMed PMID: 8352556.

36: Koyama H, Ogawa M, Kuraishi Y, Tominaga K, Yoshida M, Taguchi T. [A phase II clinical study of cis-diammine glycolato platinum, 254-S, for advanced breast cancer]. Gan To Kagaku Ryoho. 1992 Jul;19(7):1049-53. Japanese. PubMed PMID: 1626940.

37: Furuse K, Fukuoka M, Asamoto H, Niitani H, Kimura I, Sakuma A, Yamaguchi Y. [A randomized comparative study of 254-S plus vindesine (VDS) vs. cisplatin (CDDP) plus VDS in patients with advanced non-small cell lung cancer (NSCLC)]. Gan To Kagaku Ryoho. 1992 Jul;19(7):1019-26. Japanese. PubMed PMID: 1320846.

38: Noda K, Ikeda M, Yakushiji M, Nishimura H, Terashima Y, Sasaki H, Hata T, Kuramoto H, Tanaka K, Takahashi T, et al. [A phase II clinical study of cis-diammine glycolato platinum, 254-S, for cervical cancer of the uterus]. Gan To Kagaku Ryoho. 1992 Jun;19(6):885-92. Japanese. PubMed PMID: 1605666.

39: Inuyama Y, Miyake H, Horiuchi M, Hayasaki K, Komiyama S, Ota K. [A late phase II clinical study of cis-diammine glycolato platinum, 254-S, for head and neck cancers]. Gan To Kagaku Ryoho. 1992 Jun;19(6):871-7. Japanese. PubMed PMID: 1605665.

40: Inuyama Y, Miyake H, Horiuchi M, Hayasaki K, Komiyama S, Ota K. [An early phase II clinical study of cis-diammine glycolato platinum, 254-S, for head and neck cancers]. Gan To Kagaku Ryoho. 1992 Jun;19(6):863-9. Japanese. PubMed PMID: 1605664.

41: Furuse K, Fukuoka M, Kurita Y, Ariyoshi Y, Niitani H, Yoneda S, Fujii M, Hasegawa K, Nishiwaki Y, Tamura M, et al. [A phase II clinical study of cis-diammine glycolato platinum, 254-S, for primary lung cancer]. Gan To Kagaku Ryoho. 1992 Jun;19(6):879-84. Japanese. PubMed PMID: 1318698.

42: Kato T, Nishimura H, Yakushiji M, Noda K, Terashima Y, Takeuchi S, Takamizawa H, Suzuki M, Arai M, Ota M, et al. [Phase II study of 254-S (cis-diammine glycolato platinum) for gynecological cancer]. Gan To Kagaku Ryoho. 1992 May;19(5):695-701. Japanese. PubMed PMID: 1580643.

43: Taguchi T, Wakui A, Nabeya K, Kurihara M, Isono K, Kakegawa T, Ota K. [A phase II clinical study of cis-diammine glycolato platinum, 254-S, for gastrointestinal cancers. 254-S Gastrointestinal Cancer Study Group]. Gan To Kagaku Ryoho. 1992 Apr;19(4):483-8. Japanese. PubMed PMID: 1558398.

44: Akaza H, Togashi M, Nishio Y, Miki T, Kotake T, Matsumura Y, Yoshida O, Aso Y. Phase II study of cis-diammine(glycolato)platinum, 254-S, in patients with advanced germ-cell testicular cancer, prostatic cancer, and transitional-cell carcinoma of the urinary tract. 254-S Urological Cancer Study Group. Cancer Chemother Pharmacol. 1992;31(3):187-92. PubMed PMID: 1334448.